FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775649503> ?p ?o ?g. }

• W2775649503 endingPage "202" @default.
• W2775649503 startingPage "185" @default.
• W2775649503 abstract "Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of localized prostate cancer. This trend combined with declining use of brachytherapy (BT) has pushed issues and questions regarding the use of SBRT to the forefront. A systematic literature review was conducted to review the current evidence of biochemical disease-free survival (bDFS) and toxicity of SBRT in high-risk (HR) prostate cancer.A search was carried out on the PubMed and Embase databases. Studies were included if HR patients were treated using SBRT monotherapy or as a boost and bDFS was reported. Selected high-dose-rate (HDR) BT studies including HR patients from published reviews were selected to compare with SBRT results. Data from recent published phase 3 trials involving HR patients were also compared.Our search yielded 8862 articles. Of these, 20 studies with a median follow-up from 1.6 to 7 years were included in this review. The 5-year bDFS was 81% to 91% in monotherapy studies and 90% to 98% in boost studies. For reference, 19 studies that reported treating HR patients with HDR monotherapy or boost were selected. The 5-year bDFS in HDR monotherapy studies and boost studies was 85% to 93% and 72% to 93%, respectively. The incidence of late grade 3 genitourinary toxicity was 0% to 4.4% and 0% to 2.3% in SBRT monotherapy and SBRT boost studies, respectively.The evidence for SBRT in HR patients in this review is based on observational studies with relatively few patients and short follow-up (level III evidence). Based on these data and the principles surrounding treatment, SBRT boost should ideally be validated in clinical trials. SBRT monotherapy should be used cautiously in highly selected HR patients outside of a clinical trial.Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of clinically localized prostate cancer. This trend, combined with the decline in the use of brachytherapy, has pushed issues and questions regarding the use of SBRT to the forefront. A systematic literature review was conducted to establish the current evidence of biochemical and toxicity outcomes of SBRT in high-risk prostate cancer." @default.
• W2775649503 created "2017-12-22" @default.
• W2775649503 creator A5062549008 @default.
• W2775649503 creator A5089472018 @default.
• W2775649503 date "2018-05-01" @default.
• W2775649503 modified "2023-10-02" @default.
• W2775649503 title "Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?" @default.
• W2775649503 cites W1271215779 @default.
• W2775649503 cites W1515906819 @default.
• W2775649503 cites W1657345349 @default.
• W2775649503 cites W1915624591 @default.
• W2775649503 cites W1977970364 @default.
• W2775649503 cites W1979387793 @default.
• W2775649503 cites W1979665150 @default.
• W2775649503 cites W1979819510 @default.
• W2775649503 cites W1984994876 @default.
• W2775649503 cites W1996809772 @default.
• W2775649503 cites W2033944685 @default.
• W2775649503 cites W2037565714 @default.
• W2775649503 cites W2039824162 @default.
• W2775649503 cites W2040818579 @default.
• W2775649503 cites W2045398464 @default.
• W2775649503 cites W2045858226 @default.
• W2775649503 cites W2046812072 @default.
• W2775649503 cites W2049677718 @default.
• W2775649503 cites W2054899405 @default.
• W2775649503 cites W2062313368 @default.
• W2775649503 cites W2062516915 @default.
• W2775649503 cites W2063839138 @default.
• W2775649503 cites W2065848035 @default.
• W2775649503 cites W2067593558 @default.
• W2775649503 cites W2076702645 @default.
• W2775649503 cites W2078968196 @default.
• W2775649503 cites W2082179683 @default.
• W2775649503 cites W2085309775 @default.
• W2775649503 cites W2085471307 @default.
• W2775649503 cites W2086604707 @default.
• W2775649503 cites W2093867637 @default.
• W2775649503 cites W2094442174 @default.
• W2775649503 cites W2096834325 @default.
• W2775649503 cites W2097532477 @default.
• W2775649503 cites W2111549378 @default.
• W2775649503 cites W2117511763 @default.
• W2775649503 cites W2127644635 @default.
• W2775649503 cites W2133911270 @default.
• W2775649503 cites W2136266646 @default.
• W2775649503 cites W2137142118 @default.
• W2775649503 cites W2138304857 @default.
• W2775649503 cites W2141767468 @default.
• W2775649503 cites W2141944007 @default.
• W2775649503 cites W2146599397 @default.
• W2775649503 cites W2148539277 @default.
• W2775649503 cites W2152182740 @default.
• W2775649503 cites W2163954169 @default.
• W2775649503 cites W2164748078 @default.
• W2775649503 cites W2166392548 @default.
• W2775649503 cites W2245551075 @default.
• W2775649503 cites W2253196302 @default.
• W2775649503 cites W2265756519 @default.
• W2775649503 cites W2285254902 @default.
• W2775649503 cites W2286596906 @default.
• W2775649503 cites W2318410370 @default.
• W2775649503 cites W2405397027 @default.
• W2775649503 cites W2407830312 @default.
• W2775649503 cites W2469515271 @default.
• W2775649503 cites W2515581857 @default.
• W2775649503 cites W2515912193 @default.
• W2775649503 cites W2520634975 @default.
• W2775649503 cites W2534892684 @default.
• W2775649503 cites W2546206558 @default.
• W2775649503 cites W2553678345 @default.
• W2775649503 cites W2565738574 @default.
• W2775649503 cites W2569728867 @default.
• W2775649503 cites W2570618306 @default.
• W2775649503 cites W2577699706 @default.
• W2775649503 cites W2588352921 @default.
• W2775649503 cites W2591309425 @default.
• W2775649503 cites W2592153529 @default.
• W2775649503 cites W2598815466 @default.
• W2775649503 cites W2682351795 @default.
• W2775649503 cites W2725037025 @default.
• W2775649503 cites W2736966846 @default.
• W2775649503 cites W4245157701 @default.
• W2775649503 cites W4294215472 @default.
• W2775649503 cites W2296418721 @default.
• W2775649503 doi "https://doi.org/10.1016/j.prro.2017.11.008" @default.
• W2775649503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29339046" @default.
• W2775649503 hasPublicationYear "2018" @default.
• W2775649503 type Work @default.
• W2775649503 sameAs 2775649503 @default.
• W2775649503 citedByCount "24" @default.
• W2775649503 countsByYear W27756495032018 @default.
• W2775649503 countsByYear W27756495032019 @default.
• W2775649503 countsByYear W27756495032020 @default.
• W2775649503 countsByYear W27756495032021 @default.
• W2775649503 countsByYear W27756495032022 @default.
• W2775649503 countsByYear W27756495032023 @default.
• W2775649503 crossrefType "journal-article" @default.

• next